Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia. - Wikidata - wikimedia - TriplyDB

Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.

Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.

http://www.wikidata.org/entity/Q36990787

about

Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor.The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.Combined venetoclax and alvocidib in acute myeloid leukemia.Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members.Pathways and mechanisms of venetoclax resistance.S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes

P2860

Q28072745-EDBA0D59-06E8-478A-BA88-7381B7F8F9AA Q38650669-F1D1E5DD-B9CD-42EC-82BD-042097A73BDF Q42796344-C1C11F84-A6E7-4AC2-8D57-62F43AE57B24 Q45865484-25CD10B7-9F7F-4C3D-9397-9853FF0DA8BC Q47105216-04D1FD46-AEE4-45CE-BBF3-23A78C479C73 Q47716556-4321C5EE-B65B-4EAE-B8DA-A607784EC2D9 Q51160342-F2679A29-3AC8-424A-B006-F38D6C1201A1 Q54998724-CE50312A-3C10-40A9-88BE-C3CFC9486CF3 Q58695490-34DD2E3A-BEF8-465D-941B-4B9688F0589A Q58747291-94FB15BF-FC01-4D26-9548-4709A1CC1B40

P2860

Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.

http://www.wikidata.org/entity/Q36990787

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Targeting MCL-1/BCL-XL Foresta ...... 199 in Acute Myeloid Leukemia.

@en

type

label

Targeting MCL-1/BCL-XL Foresta ...... 199 in Acute Myeloid Leukemia.

@en

prefLabel

Targeting MCL-1/BCL-XL Foresta ...... 199 in Acute Myeloid Leukemia.

@en

P1433

Q36990787-DEE326BA-0515-4B45-9DC7-FCC6864551BF

P1476

Q36990787-BFAF53D4-1C2F-4864-8081-F73A58E188AE

P2093

Q36990787-340F9D7D-4112-4997-AF34-F47200C5905A

Q36990787-4DD4A907-DBC4-4F32-8AF2-EBA040ED34B0

Q36990787-5DA5FA79-95A7-4EB4-9CD4-481540DA98EF

Q36990787-5E1656CA-8593-4C5E-8B7D-D1DF67DC8E18

Q36990787-BA5BD925-35CF-4758-9443-375C7C3DD779

Q36990787-BCDAB943-CB6C-48F9-B029-5D0DBA4FCF38

Q36990787-E3B86FB5-BADA-4557-96BF-4B630195984E

Q36990787-ED371368-44F0-489F-B29C-716C2EEBD447

P2860

Q36990787-03C7AFBF-D186-4836-8F4B-67E8921736BE

Q36990787-08750DF1-AD7D-4DB0-B2EF-A64FEB32A722

Q36990787-11556AE7-52CB-43A0-915F-6615C144DE24

Q36990787-11A18A3F-0194-4D5E-9380-3EC3B9DD2E3F

Q36990787-19DC53CD-5C55-43E6-8201-ACBADA7DDB0B

Q36990787-1D497A6B-4B21-4483-8B62-26BB76F2EFEF

Q36990787-49CC6BF5-7930-4867-BAE8-05740C3F8180

Q36990787-4A65254F-2FF9-4804-AE57-DB3D31685D1F

Q36990787-5E57FB54-7A0C-436A-B6B0-D4B0D41FBC1D

Q36990787-61548A43-2577-4710-B5B6-379A66085390

P2888

Q36990787-747109D6-92AD-42B7-A666-B1A6C9436501

P304

Q36990787-D57BFEB1-6078-4BA5-B996-489D08ACF4EB

P31

Q36990787-895E8F7C-500B-42AD-90EF-C5928FA5C7AA

P356

Q36990787-0753DFF0-8428-4775-8126-6907894CAF5B

P407

Q36990787-9521C286-DBE7-48E1-BAB9-C8F639A4A8ED

P478

Q36990787-B02A00CD-256B-4C18-B852-0FF0F69C91C2

P50

Q36990787-1122193E-D59A-4042-967A-ED18A27D70E5

P577

Q36990787-928FCBB5-9045-40DD-942B-9CA255096191

P698

Q36990787-A1DB7716-06CF-40E0-9A99-73A6C843C4E0

P921

Q36990787-69E231DD-BFD1-449E-8EF0-ED5786DF69BA

Q36990787-7C6591C3-3632-4AC6-ADDF-E6F1BFE2650D

P932

Q36990787-ADAFB1B0-D938-43E0-8542-26BF01AD1713

P356

P1433

Scientific Reports

P1476

Targeting MCL-1/BCL-XL Foresta ...... -199 in Acute Myeloid Leukemia

@en

P2093

Abigail Xie

http://www.w3.org/2001/XMLSchema#string

Colin A Martz

http://www.w3.org/2001/XMLSchema#string

Cullen Roth

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Stein

http://www.w3.org/2001/XMLSchema#string

Jennifer P Tingley

http://www.w3.org/2001/XMLSchema#string

Kevin H Lin

http://www.w3.org/2001/XMLSchema#string

Kris C Wood

http://www.w3.org/2001/XMLSchema#string

Peter S Winter

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Structure-guided design of a selective BCL-X(L) inhibitor

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

P2888

P304

27696

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP27696

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Grace R Anderson

P577

2016-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27283158

http://www.w3.org/2001/XMLSchema#string

P921

P932

4901329

http://www.w3.org/2001/XMLSchema#string